Screening and identification of potential MERS-CoV papain-like protease (PLpro) inhibitors; Steady-state kinetic and Molecular dynamic studies

MERS-CoV belongs to the coronavirus group. Recent years have seen a rash of coronavirus epidemics. In June 2012, MERS-CoV was discovered in the Kingdom of Saudi Arabia, with 2,591 MERSA cases confirmed by lab tests by the end of August 2022 and 894 deaths at a case-fatality ratio (CFR) of 34.5% docu...

Full description

Bibliographic Details
Published in:	Saudi Pharmaceutical Journal
Main Authors:	Mohammed Ali Dahhas, Hamad M. Alkahtani, Ajamaluddin Malik, Abdulrahman A Almehizia, Ahmed H. Bakheit, Siddique Akber Ansar, Abdullah S. AlAbdulkarim, Lamees S.Alrasheed, Mohammad A. Alsenaidy
Format:	Article
Language:	English
Published:	Springer 2023-02-01
Subjects:	MERS-CoV PLpro Inhibitors Papain-like protease Drug Design Drug Discovery Inhibitors Nonstructural proteins
Online Access:	http://www.sciencedirect.com/science/article/pii/S1319016422003061

Similar Items

Computational study of the binding orientation and affinity of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-1 considering the protein flexibility by using molecular dynamics and cross-docking
by: Luis Castillo-Campos, et al.
Published: (2023-06-01)

Benchmarking biomolecular force fields for molecular dynamics simulations of native fold and enzymatic activity of SARS-CoV-2 papain-like protease
by: Kateryna O. Lohachova, et al.
Published: (2025-07-01)

The Virtual Screening and Molecular Docking Study of New Inhibitors for SARS-COV-2 Papain-Like Protease (PLpro)
by: Necmettin Pirinççioğlu, et al.
Published: (2025-05-01)

Design, synthesis, and binding analysis of target-specific covalent inhibitors of SARS-CoV-2 papain-like protease
by: Martynas Bagdonas, et al.
Published: (2025-12-01)

Modeling of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-2 considering the protein flexibility by using molecular dynamics and cross-docking
by: Jorge Luis Valdés-Albuernes, et al.
Published: (2024-03-01)

Computational modeling and inhibition of SARS-COV-2 Papain-like protease enzyme: A potential therapeutic approach for COVID-19
by: Auwal Rabiu Auwal, et al.
Published: (2024-09-01)

Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs
by: Valentina L. Kouznetsova, et al.
Published: (2020-09-01)

NMR screening of low molecular weight inhibitors targeting the papain‐like protease (PLPro) of SARS‐CoV‐2
by: Dennis J. Pyper, et al.
Published: (2025-10-01)

Crystal structure of SARS-CoV-2 papain-like protease
by: Xiaopan Gao, et al.
Published: (2021-01-01)

Flavonoids Derived from the Roots of <i>Lespedeza bicolor</i> Inhibit the Activity of SARS-CoV Papain-like Protease
by: Hyun Sim Woo, et al.
Published: (2024-11-01)

Utilizing sinapic acid as an inhibitory antiviral agent against MERS-CoV PLpro
by: Mudassar Shahid, et al.
Published: (2024-04-01)

A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease
by: Stephanie Patchett, et al.
Published: (2021-09-01)

Myricetin inhibits transmissible gastroenteritis virus replication by targeting papain-like protease deubiquitinating enzyme activity
by: Jiahao Fan, et al.
Published: (2024-07-01)

Isolation of natural inhibitors of papain obtained from Carica papaya latex
by: Rubens Monti, et al.
Published: (2004-09-01)

Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes
by: Jinlin Tan, et al.
Published: (2022-09-01)

Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity
by: Anasha Kawall, et al.
Published: (2023-01-01)

In-cell bioluminescence resonance energy transfer (BRET)-based assay uncovers ceritinib and CA-074 as SARS-CoV-2 papain-like protease inhibitors
by: Mei Li, et al.
Published: (2024-12-01)

Insights for Future Pharmacology: Exploring Phytochemicals as Potential Inhibitors Targeting SARS-CoV-2 Papain-like Protease
by: Jawaria Jabeen, et al.
Published: (2024-08-01)

Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations
by: Anastasiia I. Petushkova, et al.
Published: (2020-09-01)

9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2
by: Kabita Pandey, et al.
Published: (2025-02-01)

Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches
by: Mubarak A. Alamri, et al.
Published: (2020-12-01)

Analysis of Structures of SARS-CoV-2 Papain-like Protease Bound with Ligands Unveils Structural Features for Inhibiting the Enzyme
by: Ann Varghese, et al.
Published: (2025-01-01)

Unveiling the mechanism of action of a novel natural dual inhibitor of SARS-CoV-2 Mpro and PLpro with molecular dynamics simulations
by: Xiaoxia Gu, et al.
Published: (2025-01-01)

SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment
by: B.Sc. Sara Protić, et al.
Published: (2024-11-01)

Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro
by: Ahmed L. Alaofi, et al.
Published: (2022-11-01)

Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2
by: Miao Zheng, et al.
Published: (2024-07-01)

Statine-based peptidomimetics as SARS-CoV-2 Papain-like protease inhibitors: in Silico and in vitro studies
by: Raiane Dandara Pereira Pimentel, et al.
Published: (2025-07-01)

Interaksi Molekuler Senyawa D-Manitol (Kulit Kopi) terhadap PLPro
by: Yohanes Bare, et al.
Published: (2022-10-01)

Exploring the medicinal potential of Dark Chemical Matters (DCM) to design promising inhibitors for PLpro of SARS-CoV-2 using molecular screening and simulation approaches
by: Abbas Khan, et al.
Published: (2023-10-01)

Virtual Screening and Inhibition of Middle East Respiratory Syndrome Coronavirus Replication by Targeting Papain-like Protease
by: Mahmoud Kandeel, et al.
Published: (2021-10-01)

Extraction, identification and activity of Papain from Iran
by: M.H. Tabaei, et al.
Published: (2006-01-01)

Structure and functions of Mer, an innate immune checkpoint
by: Eric Ubil, et al.
Published: (2023-10-01)

Purification and Characterization of a Novel Thermostable Papain Inhibitor from <i>Moringa oleifera</i> with Antimicrobial and Anticoagulant Properties
by: Juliana Cotabarren, et al.
Published: (2021-04-01)

Antisolvent Crystallization of Papain
by: Sasitorn Boonkerd, et al.
Published: (2023-12-01)

Immobilization of Papain in Chitosan Membranes as a Potential Alternative for Skin Wounds
by: Anne Emmanuelle Câmara da Silva Melo, et al.
Published: (2023-11-01)

Suppression of SARS-CoV-2 nucleocapsid protein dimerization by ISGylation and its counteraction by viral PLpro
by: Wonjin Bang, et al.
Published: (2024-10-01)

Identification of Triazolopyrimidinyl Scaffold SARS-CoV-2 Papain-Like Protease (PL<sup>pro</sup>) Inhibitor
by: Sebastjan Kralj, et al.
Published: (2024-01-01)

Comparative study of the stability of free and modified papain incorporated in topical formulations
by: Claudinéia Aparecida Sales de Oliveira Pinto, et al.
Published: (2011-12-01)

Purification of papain from fresh latex of Carica papaya
by: Rubens Monti, et al.
Published: (2000-01-01)

The development of papain‐like protease from SARS‐CoV‐2, a potential drug target for antiviral screening: A review
by: Riswanto Napitupulu, et al.
Published: (2023-09-01)